Volpara simplifying breast cancer communication for women with AI-driven imagery

At a time when women are more aware of potential health issues than ever, Volpara Health (ASX: VHT) is set to drastically improve how breast cancer is talked about with imaging technology driven by artificial intelligence that will help prevent advanced stage breast cancer.

The imagery will be provided to women in collaboration with Sheila R. Veloz Breast Center at Henry Mayo Newhall Hospital in California and will be an alternative means of communication from the medical jargon-heavy letters which have been the long-time norm, often to the confusion of patients.

“We send patient letters full of text that can be difficult to understand. Partnering with Volpara will enable us to provide images that speak far more than text can ever do,” said Mara Shay, RN Manager of Women’s Imaging Services at the Sheila R. Veloz Breast Center.

“This communication tool is going to dramatically improve our patients’ understanding of breast composition.”

The AI technology that will be applied to breast imaging has been developed by Volpara and scans mammograms objectively to measure breast composition and density of which reporting is mandated in many US States, as well as recommended follow-up options.

“Millions of women comply with their annual screening, yet they have never seen what their breasts look like in their actual mammogram,” said Katherine Singson, US CEO of Volpara Health.

“The addition of a woman’s own images will make it easier to grasp the important concept of breast composition and tissue density, empowering women to better understand their breast health.

“We know our bra size throughout our life. Why shouldn’t women understand their breast composition given it’s a simple concept, especially if it could save their lives.”

According to the American Cancer Society, one in eight women in the United States will be diagnosed with breast cancer in her lifetime.

The Volpara Breast Heath Platform is designed to help clinics provide personalised screening at every step of the patient journey by optimising clinical decision support, continuous quality improvement, and practice and management with more than 10.5 million American women using a Volpara screening product annually.